Tagged with generics,

Mexico Francisco Kuri Breña, director of new developments at local Mexican player Landsteiner, shares the company’s existing positioning as one of the top 10 suppliers of generic medicines to the Mexican government, their exciting pipeline of new projects including in genomic medicine and upcoming plans to invest in medical marijuana once…

Mexico CP Maria del Socorro España Lomeli, executive director of the Mexican generics industry association ANAFAM, discusses the challenges with regard to the ‘new rules of the game’ in Mexico’s healthcare sector since 2018, the willingness of the Mexican pharmaceutical industry to be a trusted ally to the public healthcare system,…

Romania Arina Gholmieh introduces the Romanian affiliate of Egis, a leading pharma manufacturer in the Central and Eastern Europe (CEE) region. Gholmieh highlights the difficulties that pharma companies, and especially generic producers, face in Romania: clawback tax, pricing methodology, and a low penetration rate of biosimilar medicines.   We are passing…

Opinion AAM Interim President Jeff Francer outlines the vital role that biosimilar and generics firms will play in filling supply chain gaps during the ongoing coronavirus pandemic.   Like the rest of society, executive and scientific teams working in the US generic and biosimilar pharmaceutical industries have never experienced anything quite…

Morocco Yassine Houbachi discusses his strategy for leading Moroccan generics player Polymedic, the market environment in Morocco, and what future challenges may be. In addition, Houbachi introduces RIM Pharma, an innovative young company which is expanding access to oncology diagnostics in Morocco.   The market being stagnant, prices are dropping and…

Morocco Multinational pharmaceutical companies are increasingly seeing Morocco as a top manufacturing destination for the African continent. Firms from Europe, Asia-Pacific and the US are investing millions of dollars in bolstering and expanding their drug production facilities in the North African nation thanks to its strategic location, price-competitiveness, and comparatively developed…

India The US generics market stood at USD 69 billion in 2018 and is expected to grow to USD 86 billion by 2022. Made with Visme Infographic Maker   Abbreviated New Drug Applications (ANDAs), whereby a company seeks authorisation from the US FDA for a generic copy of a previously approved…

India A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market.   Now accounting for over 90 percent of all prescriptions dispensed in the USA, generic drugs play a vital role within US healthcare and have come a long way since their use…

Morocco Ensuring the country’s “sanitary sovereignty” has long been a key policy for Morocco and its government. In order to encourage the local production of drugs, Law 17-04 was promulgated in 2006 requiring pharma companies to operate a manufacturing, control and storage site in order to apply for marketing authorization.  …

Romania Simona Cocos of Zentiva Romania explains how the affiliate has developed since its separation from Sanofi and how recent acquisitions have impacted local operations. She shares how the extremely diversified portfolio is a key strength and how new ventures in consumer health are helping boost performance. Cocos adds that continued…

Opinion Jonathan Kimball of the Association for Accessible Medicines (AAM) in the USA outlines why the signing of the US-Mexico-Canada Agreement (USMCA) in January 2020 may mark a turning point for greater access to generic and biosimilar medicines globally.   US trading partners should take note. There is no longer a…

Belgium Teva Pharma Belgium’s Eric Deschepper outlines how the global group’s restructuring has impacted its Belgian operations, its realignment from a pure generics to a specialty pharma player, and how the company is uniquely positioned to help Belgium achieve its healthcare goals.   We are in fact on both sides of…